|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SIRT7 |
Gene summary for SIRT7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SIRT7 | Gene ID | 51547 |
| Gene name | sirtuin 7 | |
| Gene Alias | SIR2L7 | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9NRC8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51547 | SIRT7 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.30e-08 | 5.58e-01 | -0.1808 |
| 51547 | SIRT7 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.56e-03 | 2.61e-01 | -0.0811 |
| 51547 | SIRT7 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.59e-07 | 3.09e-01 | -0.1954 |
| 51547 | SIRT7 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.38e-03 | 7.64e-01 | -0.2602 |
| 51547 | SIRT7 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.85e-03 | 5.89e-01 | -0.2196 |
| 51547 | SIRT7 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.34e-05 | 4.13e-01 | -0.1526 |
| 51547 | SIRT7 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.69e-04 | 3.39e-01 | -0.1464 |
| 51547 | SIRT7 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.74e-04 | 2.47e-01 | -0.1001 |
| 51547 | SIRT7 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.43e-07 | 3.17e-01 | -0.059 |
| 51547 | SIRT7 | A002-C-205 | Human | Colorectum | FAP | 1.15e-02 | -1.40e-01 | -0.1236 |
| 51547 | SIRT7 | A002-C-116 | Human | Colorectum | FAP | 7.37e-03 | -1.05e-01 | -0.0452 |
| 51547 | SIRT7 | LZE2T | Human | Esophagus | ESCC | 2.02e-02 | 3.72e-01 | 0.082 |
| 51547 | SIRT7 | LZE7T | Human | Esophagus | ESCC | 2.59e-09 | 3.56e-01 | 0.0667 |
| 51547 | SIRT7 | LZE20T | Human | Esophagus | ESCC | 1.04e-05 | 2.18e-01 | 0.0662 |
| 51547 | SIRT7 | LZE22T | Human | Esophagus | ESCC | 2.78e-14 | 5.42e-01 | 0.068 |
| 51547 | SIRT7 | LZE24T | Human | Esophagus | ESCC | 4.83e-34 | 7.81e-01 | 0.0596 |
| 51547 | SIRT7 | LZE21T | Human | Esophagus | ESCC | 5.65e-10 | 6.14e-01 | 0.0655 |
| 51547 | SIRT7 | P1T-E | Human | Esophagus | ESCC | 7.67e-22 | 6.81e-01 | 0.0875 |
| 51547 | SIRT7 | P2T-E | Human | Esophagus | ESCC | 1.36e-15 | 2.79e-01 | 0.1177 |
| 51547 | SIRT7 | P4T-E | Human | Esophagus | ESCC | 6.07e-18 | 3.66e-01 | 0.1323 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00060941 | Liver | Cirrhotic | gluconeogenesis | 32/4634 | 75/18723 | 5.00e-04 | 3.98e-03 | 32 |
| GO:00106751 | Liver | Cirrhotic | regulation of cellular carbohydrate metabolic process | 54/4634 | 146/18723 | 6.53e-04 | 4.96e-03 | 54 |
| GO:200102011 | Liver | Cirrhotic | regulation of response to DNA damage stimulus | 75/4634 | 219/18723 | 9.75e-04 | 6.89e-03 | 75 |
| GO:005105211 | Liver | Cirrhotic | regulation of DNA metabolic process | 114/4634 | 359/18723 | 1.48e-03 | 9.85e-03 | 114 |
| GO:00015035 | Liver | Cirrhotic | ossification | 127/4634 | 408/18723 | 1.89e-03 | 1.19e-02 | 127 |
| GO:00064791 | Liver | Cirrhotic | protein methylation | 61/4634 | 181/18723 | 4.13e-03 | 2.21e-02 | 61 |
| GO:00082131 | Liver | Cirrhotic | protein alkylation | 61/4634 | 181/18723 | 4.13e-03 | 2.21e-02 | 61 |
| GO:00165711 | Liver | Cirrhotic | histone methylation | 49/4634 | 141/18723 | 4.90e-03 | 2.56e-02 | 49 |
| GO:0035601 | Liver | Cirrhotic | protein deacylation | 39/4634 | 112/18723 | 1.08e-02 | 4.75e-02 | 39 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:003238621 | Liver | HCC | regulation of intracellular transport | 231/7958 | 337/18723 | 1.99e-22 | 3.40e-20 | 231 |
| GO:000691322 | Liver | HCC | nucleocytoplasmic transport | 208/7958 | 301/18723 | 5.51e-21 | 8.12e-19 | 208 |
| GO:005116922 | Liver | HCC | nuclear transport | 208/7958 | 301/18723 | 5.51e-21 | 8.12e-19 | 208 |
| GO:003315721 | Liver | HCC | regulation of intracellular protein transport | 165/7958 | 229/18723 | 8.37e-20 | 1.15e-17 | 165 |
| GO:190332022 | Liver | HCC | regulation of protein modification by small protein conjugation or removal | 167/7958 | 242/18723 | 4.99e-17 | 4.72e-15 | 167 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SIRT7 | SNV | Missense_Mutation | c.1076C>G | p.Ser359Trp | p.S359W | Q9NRC8 | protein_coding | tolerated(0.18) | possibly_damaging(0.652) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SIRT7 | SNV | Missense_Mutation | c.1191N>C | p.Lys397Asn | p.K397N | Q9NRC8 | protein_coding | deleterious_low_confidence(0) | benign(0.092) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SIRT7 | SNV | Missense_Mutation | novel | c.710T>C | p.Val237Ala | p.V237A | Q9NRC8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| SIRT7 | SNV | Missense_Mutation | rs781471662 | c.1042C>T | p.Arg348Cys | p.R348C | Q9NRC8 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| SIRT7 | SNV | Missense_Mutation | rs757485586 | c.1043G>A | p.Arg348His | p.R348H | Q9NRC8 | protein_coding | tolerated(0.09) | benign(0.018) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SIRT7 | SNV | Missense_Mutation | novel | c.1185N>C | p.Lys395Asn | p.K395N | Q9NRC8 | protein_coding | deleterious_low_confidence(0.01) | benign(0.436) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| SIRT7 | SNV | Missense_Mutation | rs200982525 | c.952G>A | p.Val318Ile | p.V318I | Q9NRC8 | protein_coding | deleterious(0.03) | possibly_damaging(0.459) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| SIRT7 | SNV | Missense_Mutation | rs190336639 | c.994N>A | p.Ala332Thr | p.A332T | Q9NRC8 | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| SIRT7 | SNV | Missense_Mutation | rs747584480 | c.1031N>T | p.Ala344Val | p.A344V | Q9NRC8 | protein_coding | deleterious(0.02) | benign(0.352) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SIRT7 | SNV | Missense_Mutation | c.941A>C | p.Lys314Thr | p.K314T | Q9NRC8 | protein_coding | deleterious(0) | benign(0.265) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |